-
Brazil suspends Covaxin order over graft allegations
The Covaxin contract to Brazil landed in controversy after the South American country's Attorney General reportedly launched a probe into the deal
-
India’s Covaxin effectively neutralises Delta variant of Covid, says NIH
Covaxin generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2.
-
Govt expert panel accepts Covaxin phase-3 trial data
The indigenously developed vaccine has shown 77.8% efficacy in the trial conducted on 25,800 subjects
-
'Rs150 per Covaxin dose to govt not sustainable in long run'
The Centre's supplying price is pushing the pricing structure for the private sector upward, Bharat Biotech said
-
Sputnik V: These two private hospitals in Delhi will give jabs by end of this week
After Covishield and Covaxin, Sputnik V is the third vaccine to be approved by the government for use in India
-
FDA rejects emergency use authorization for Bharat Biotech’s Covaxin
FDA has asked Ocugen, the US partner of Bharat Biotech to launch an additional trial so that it can file for a full approval
-
'Expect peer review of Covaxin's Phase 3 trials data in Q4'
Suchitra Ella, Joint Managing Director of Bharat Biotech, said Covaxin has reached private hospitals in as many as 28 cities
-
Covid-19 vaccine price for private hospitals: Covishield at Rs 780 a dose, Covaxin at Rs 1410
Vaccine price: The Health Ministry has asked states to ensure that the prices declared by various private CVCs do not exceed the ceiling
-
Ocugen pays $15 million upfront to Bharat Biotech for Covaxin rights in Canada
Bharat Biotech and Ocugen Inc have entered into a definitive agreement to co-develop, supply, and commercialise Covaxin for the US market.
-
Vaccination: Reins back in its hand, the Centre should ensure delivery
With the reins of the vaccination programme back in its hands, the Centre cannot afford disorder in the procurement and supply of the jabs to the stat
